Certara, Inc.
Certara, Inc. (CERT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CERT · as of Jun 9, 2026
Key Statistics
Explore Certara, Inc. Data
cert stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 16 · Buy rate: 50.0%
The CERT analyst consensus is Buy, based on ratings from 16 Wall Street analysts over the past 3 months. The average 12-month price target is $9.00, representing +72.41% upside from the current price of $5.22.
Competitors & Peers
cert competitorsCERT
AVAH
CLOV
NHC
OMCL
PGNYStock Performance
Full HistoryAbout Certara, Inc.
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and precl…
what is certara, inc. · cert stock overview · certara, inc. company profile · who is certara, inc. ceo · cert NASDAQ · certara, inc. headquarters · certara, inc. business segments
About Stock Overview & Key Data
Certara, Inc. (CERT) is a Healthcare company in the Medical - Healthcare Information Services industry, listed on NASDAQ since Dec 11, 2020. As of the latest trading session, CERT stock price is $5.22, with a market capitalization of $812.0M. The stock has returned -54.93% over the past 12 months and -39.78% year-to-date.
According to 16 Wall Street analysts, the consensus rating for Certara, Inc. stock is Buy, with an average 12-month price target of $9.00. In fiscal year 2025, Certara, Inc. reported revenue of $418.8M and net income of -$1.6M. For detailed data — including Certara, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Certara, Inc. (CERT) stock price is $5.22. The stock is traded on NASDAQ under the ticker symbol CERT. The 52-week range is $4.45 – $13.88.